Active, not recruitingPHASE2, PHASE3NCT04850118
A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP
Studying Retinitis pigmentosa
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Beacon Therapeutics
- Principal Investigator
- Carrie ReichleyBeacon Therapeutics
- Intervention
- rAAV2tYF-GRK1-hRPGRco(biological)
- Enrollment
- 85 enrolled
- Eligibility
- 12-50 years · MALE
- Timeline
- 2024 – 2029
Study locations (24)
- Retina Macula Institute of Arizona, Scottsdale, Arizona, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- University of Florida Health Jacksonville, Department of Ophthalmology, Jacksonville, Florida, United States
- Bascom Palmer Eye Institute- University of Miami, Miami, Florida, United States
- Midwest Eye Institute (Retina Partners Midwest), Carmel, Indiana, United States
- Wilmer Eye Institute at Johns Hopkins, Baltimore, Maryland, United States
- Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Duke Eye Center, Durham, North Carolina, United States
- Cincinnati Eye Institute, Cincinnati, Ohio, United States
- Cole Eye Institute - Cleveland Clinic, Cleveland, Ohio, United States
- Casey Eye Institute, OHSU, Portland, Oregon, United States
- The Center for Advanced Retinal & Ocular Therapeutics University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
- Mid Atlantic Retina, Philadelphia, Pennsylvania, United States
- University of Pittsburgh, Pittsburgh, Pennsylvania, United States
- +9 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04850118 on ClinicalTrials.govOther trials for Retinitis pigmentosa
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07502664Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)Ray Therapeutics, Inc.
- RECRUITINGNANCT07266584Restoration of Central Vision With PRIMA in Patients With Photoreceptor DegenerationScience Corporation
- RECRUITINGNANCT07292987Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts HospitalCentre Hospitalier National d'Ophtalmologie des Quinze-Vingts
- RECRUITINGNCT07228793Natural History Study of Patients With EYS-Associated RPSensor Technology for Deafblind
- RECRUITINGPHASE1, PHASE2NCT06891885A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis PigmentosaSumitomo Pharma America, Inc.
- RECRUITINGPHASE2NCT07174726A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis PigmentosaBeacon Therapeutics
- RECRUITINGPHASE2NCT06628947A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis PigmentosaKiora Pharmaceuticals, Inc.
- RECRUITINGPHASE2NCT06912633Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)jCyte, Inc